(BBIO) BridgeBio Pharma - Overview
Stock: Genetic Medicines, Small Molecules, Gene Therapy, Drug Development
| Risk 5d forecast | |
|---|---|
| Volatility | 53.7% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.61 |
| Alpha | 83.24 |
| Character TTM | |
|---|---|
| Beta | 1.325 |
| Beta Downside | 1.206 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.08% |
| CAGR/Max DD | 1.37 |
EPS (Earnings per Share)
Revenue
Description: BBIO BridgeBio Pharma March 01, 2026
BridgeBio Pharma (NASDAQ: BBIO) is a commercial-stage biopharma focused on developing transformative medicines for rare genetic diseases and cancers, leveraging a pipeline that spans small-molecule oral drugs, protein antagonists, and gene-therapy platforms.
Key pipeline assets include Attruby (a next-generation TTR stabilizer for ATTR-CM), low-dose infigratinib (FGFR1-3 inhibitor) currently in a Phase 3 double-blind trial for achondroplasia and a Phase 2/3 study for hypochondroplasia, Encaleret (CaSR antagonist) in Phase 3 for autosomal dominant hypocalcemia type 1, and BBP-418 (glycosylation substrate pro-drug) in Phase 3 for LGMD2I/R9. Recent data show the infigratinib Phase 3 trial met its primary endpoint with a 45 % improvement in height velocity versus placebo, and Attruby received Fast Track designation from the FDA in Q4 2025.
Financially, BridgeBio reported a Q4 2025 revenue of $12.4 million and a net loss of $78 million, while maintaining a cash runway of roughly $420 million, enough to fund operations into mid-2028. The company’s market capitalization stands at approximately $2.3 billion, and R&D spend represents about 38 % of total expenses, underscoring its commitment to advancing the pipeline.
The biotechnology sector continues to benefit from robust capital inflows, with U.S. biotech IPO activity up 22 % year-over-year and gene-therapy market revenue projected to exceed $15 billion by 2027, providing a favorable backdrop for companies like BridgeBio that target high-unmet-need rare diseases.
For a deeper dive into BridgeBio’s valuation metrics, consider exploring ValueRay’s analyst tools.
Headlines to watch out for
- Attruby sales growth drives revenue
- Pipeline success in late-stage trials boosts valuation
- Regulatory approval for new drugs expands market
- Clinical trial failures increase R&D costs
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -729.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA 8.72 > 1.0 |
| NWC/Revenue: 92.76% < 20% (prev 255.2%; Δ -162.4% < -1%) |
| CFO/TA -0.48 > 3% & CFO -445.9m > Net Income -729.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (197.2m) vs 12m ago 4.12% < -2% |
| Gross Margin: 94.37% > 18% (prev 0.98%; Δ 9.34k% > 0.5%) |
| Asset Turnover: 54.12% > 50% (prev 24.14%; Δ 29.98% > 0%) |
| Interest Coverage Ratio: -6.10 > 6 (EBITDA TTM -622.5m / Interest Expense TTM 103.5m) |
Altman Z'' -15.00
| A: 0.50 (Total Current Assets 753.7m - Total Current Liabilities 288.0m) / Total Assets 936.0m |
| B: -4.08 (Retained Earnings -3.82b / Total Assets 936.0m) |
| C: -0.68 (EBIT TTM -631.5m / Avg Total Assets 927.7m) |
| D: -1.27 (Book Value of Equity -3.82b / Total Liabilities 3.01b) |
| Altman-Z'' Score: -15.95 = D |
Beneish M 1.00
| DSRI: 13.05 (Receivables 139.4m/4.72m, Revenue 502.1m/221.9m) |
| GMI: 1.04 (GM 94.37% / 98.25%) |
| AQI: 0.89 (AQ_t 0.18 / AQ_t-1 0.20) |
| SGI: 2.26 (Revenue 502.1m / 221.9m) |
| TATA: -0.30 (NI -729.3m - CFO -445.9m) / TA 936.0m) |
| Beneish M-Score: 7.46 (Cap -4..+1) = D |
What is the price of BBIO shares?
Over the past week, the price has changed by -3.51%, over one month by +0.93%, over three months by -11.09% and over the past year by +84.15%.
Is BBIO a buy, sell or hold?
- StrongBuy: 10
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 100.6 | 46.8% |
| Analysts Target Price | 100.6 | 46.8% |
BBIO Fundamental Data Overview March 22, 2026
P/B = 123.6828
Revenue TTM = 502.1m USD
EBIT TTM = -631.5m USD
EBITDA TTM = -622.5m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 17.4m USD (from shortTermDebt, last quarter)
Debt = 2.73b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.16b USD (from netDebt column, last quarter)
Enterprise Value = 15.43b USD (13.29b + Debt 2.73b - CCE 587.5m)
Interest Coverage Ratio = -6.10 (Ebit TTM -631.5m / Interest Expense TTM 103.5m)
EV/FCF = -33.72x (Enterprise Value 15.43b / FCF TTM -457.6m)
FCF Yield = -2.97% (FCF TTM -457.6m / Enterprise Value 15.43b)
FCF Margin = -91.14% (FCF TTM -457.6m / Revenue TTM 502.1m)
Net Margin = -145.3% (Net Income TTM -729.3m / Revenue TTM 502.1m)
Gross Margin = 94.37% ((Revenue TTM 502.1m - Cost of Revenue TTM 28.3m) / Revenue TTM)
Gross Margin QoQ = 90.0% (prev 94.56%)
Tobins Q-Ratio = 16.48 (Enterprise Value 15.43b / Total Assets 936.0m)
Interest Expense / Debt = 0.44% (Interest Expense 12.0m / Debt 2.73b)
Taxrate = 21.0% (US default 21%)
NOPAT = -498.9m (EBIT -631.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.62 (Total Current Assets 753.7m / Total Current Liabilities 288.0m)
Debt / Equity = -1.31 (negative equity) (Debt 2.73b / totalStockholderEquity, last quarter -2.08b)
Debt / EBITDA = -3.47 (negative EBITDA) (Net Debt 2.16b / EBITDA -622.5m)
Debt / FCF = -4.72 (negative FCF - burning cash) (Net Debt 2.16b / FCF TTM -457.6m)
Total Stockholder Equity = -1.86b (last 4 quarters mean from totalStockholderEquity)
RoA = -78.62% (Net Income -729.3m / Total Assets 936.0m)
RoE = 39.18% (negative equity) (Net Income TTM -729.3m / Total Stockholder Equity -1.86b)
RoCE = 7.01k% (out of range, set to none) (EBIT -631.5m / Capital Employed (Equity -1.86b + L.T.Debt 1.85b))
RoIC = 3.64k% (out of range, set to none) (NOPAT -498.9m / Invested Capital -13.7m)
WACC = 8.89% (E(13.29b)/V(16.02b) * Re(10.64%) + D(2.73b)/V(16.02b) * Rd(0.44%) * (1-Tc(0.21)))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.53%
[DCF] Fair Price = unknown (Cash Flow -457.6m)
EPS Correlation: -18.21 | EPS CAGR: 18.68% | SUE: -0.65 | # QB: 0
Revenue Correlation: 60.93 | Revenue CAGR: 233.0% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.52 | Chg7d=-0.072 | Chg30d=-0.032 | Revisions Net=+1 | Analysts=4
EPS current Year (2026-12-31): EPS=-2.14 | Chg7d=-0.184 | Chg30d=-0.484 | Revisions Net=+1 | Growth EPS=+43.3% | Growth Revenue=+82.2%
EPS next Year (2027-12-31): EPS=0.00 | Chg7d=-0.160 | Chg30d=-0.978 | Revisions Net=+0 | Growth EPS=+100.1% | Growth Revenue=+75.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)